Tag: Pharmaceuticals

North & South America Mineral Supplement Tablets Market Worth $3.8 Billion By 2027

The North and South America mineral supplement tablets market size is expected to reach USD 3.8 billion by 2027, according to a new report by Grand View Research, Inc. The market is projected to register a CAGR of 4.7% during the forecast period. Higher prevalence of diseases such as osteoporosis, anemia, cancer, obesity, and diabetes coupled with increasing consumer awareness regarding health and fitness is anticipated to drive the growth.

Increasing mergers and acquisitions, new product launches, partnerships, and investments in mineral supplements is also anticipated to positively impacting the growth. In September 2019, NOW Foods acquired SuperNutrition supplement company to expand its product portfolio while keeping the formulation principles of the founder and the business ethics of the family in consideration.

Rising geriatric population is expected to boost the demand for vitamin, mineral, and other supplements in near future. Growing consumer focus on disease prevention over treatment is also positively impacting the market growth. Consumers are more focused on disease prevention than on treatment. This factor is projected to bode well for the product demand in both North and South America.

Moreover, emergence of e-commerce platforms, presence of a large consumer base, and rising channel proliferation, are the factors driving the market growth. Recent product innovations in the market and growing mergers and acquisitions are resulting in market expansion, which is further contributing to the growth of the market for mineral supplements. For instance, In April 2018, Youcam partnered with Amway and launched Artistry-a mobile application-for an innovative Augmented Reality (AR) shopping experience and redefining customer experience.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/north-south-america-mineral-supplement-tablets-market

Further key findings from the study suggest:

  • Calcium emerged as the largest product segment in 2019 owing to high nutrition deficiencies, especially among women and the elderly in developing countries
  • Factors such as rising adoption of e-commerce platforms, presence of a large consumer base, and rising channel proliferation, are anticipated to create growth opportunities for the market in South America
  • In 2019, North America held the highest revenue share owing to rise in prevalence of mineral deficiencies, especially that of calcium and iron

Cannabidiol Nutraceuticals Market Size Worth $17.4 Billion By 2026

The global CBD nutraceuticals market is projected to reach USD 17.4 billion by 2026, according to a new report by Grand View Research, Inc. It is anticipated to exhibit a CAGR of 18.8% during the forecast period. Introduction of the 2018 Farm Bill that legalized hemp cultivation and hemp-derived products in U.S., rising consumer preference for plant-based ingredients in dietary supplements, and awareness regarding the health benefits of cannabidiol are some of the factors powering the market growth. However, the easy availability of alternative products is obstructing market growth.

CBD tinctures dominated the global Cannabidiol (CBD) nutraceuticals market in 2018, with a revenue share of 42.6%. Increasing acceptance of cannabidiol for health and wellness purposes coupled with high bioavailability of tinctures when administered sublingually are the major factors responsible for this large market share. On the other hand, capsules and soft gels are anticipated to be the fastest-growing product type over the forecast period, as they are travel-friendly and convenient to carry in public places. However, many consumers dislike the raw taste and texture of cannabidiol and so they are switching towards capsules and softgels.

Based on the sales channel, retail store segment dominated the CBD (Cannabidiol) nutraceuticals market in 2018, as consumers prefer retail stores for buying dietary supplements due to attractive pricing. On the other hand, the online sales channel is expected to expand at the fastest CAGR over the forecast period owing to the rise in the preference for online shopping. Furthermore, the new entrants in the CBD nutraceuticals space, find online sales channel a much economical alternative than a retail storefront.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/cbd-nutraceuticals-market

Further key findings from the report suggest:

  • In 2018, CBD tinctures dominated the Cannabidiol nutraceuticals market with a revenue share of 42.6%, due to the higher bioavailability than other product types
  • The online sales channel is projected to witness the fastest growth rate over the forecast period. Many companies are opting for this channel, as it is a faster way to reach the target audience
  • Some of the major market players are Medical Marijuana Inc.; CV Sciences Inc.; CHARLOTTE’S WEB; Irwin Naturals; and MGC Pharma

U.S. Cannabis Market Size Worth $31.7 Billion By 2025

The U.S. cannabis market size is expected to reach USD 31.7 billion by 2025, exhibiting a CAGR of 14.5% during the forecast period, according to a new study by Grand View Research, Inc. Increasing adoption of medical marijuana for treatment of various medicinal conditions, along with addition of various applications in medical marijuana programs of each state, is expected to drive the market over the forecast period.

The use of cannabis for medical purposes is gaining momentum due to its recent legalization in various states of the country. The application areas for cannabis can be classified into chronic pain, mental disorders, cancer, and other medicinal conditions. Chronic pain accounted for the largest share by application in 2018 and is expected to grow at a lucrative rate over the forecast period. This due to a large patient base and increasing number of medical conditions/trauma associated with chronic pain. On the other hand, marijuana use for treatment of mental disorders is anticipated to be the fastest growing segment over the forecast period. 

The buds segment dominated the U.S. cannabis market in 2018, with a revenue of USD 7.8 billion, and is expected to grow at a lucrative rate over the forecast period. Dried buds are used for smoking and have found widespread application in treating a variety of diseases such as cancer and Alzheimer’s. Furthermore, buds are more affordable than oral products or tinctures, which increases its adoption.

California accounted for the largest market share in U.S. in 2018 and is expected to grow at a significant rate over the forecast period. The market expansion in this state can be attributed to expanding population base and growing number of marijuana businesses. Furthermore, the state has also legalized both forms of marijuana use i.e. medical and recreational, which considerably increases product adoption.

The industry is expected to witness significant growth due to alterations in regulatory norms related to the commercial usage of marijuana and decline in its illicit sales. For instance, the use of medical marijuana has been legalized in 33 states in the U.S. and the District of Columbia, owing to continuous political movement supporting its legalization across the remaining states. Moreover, policymakers are focusing on generating tax revenues in order to aid businesses by providing suitable funding.

Some of the players operating in the U.S. market are Green Man Cannabis, Los Suoenos Farms LLC, and Vireo Health of New York, which operate in their individual states as interstate trading is banned in the country. With increasing pressure on federal legalization of cannabis in U.S., the market is expected to significantly increase after its federal approval in the next few years.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/us-cannabis-market

Further key findings from the report suggest:

  • California accounts for the largest market share in the U.S. owing to high demand, large population base, and significant number of cannabis businesses operating in the state
  • The medical marijuana segment dominated the market as it is legal in a greater number of states compared to states that have legalized the product for recreational purposes
  • Consumption of marijuana oil does not have any adverse impact on the body as compared to smoking cannabis. This is expected to boost demand for oil, especially for medical use, over the projected timeframe
  • Buds dominated the U.S. cannabis market in 2018, with a revenue of USD 7.8 billion, owing to its affordable pricing compared to oils and tinctures. The segment is anticipated to grow at a significant rate over the forecast period

Tumor Necrosis Factor Inhibitor Drugs Market Worth $42.1 Billion By 2026

The global tumor necrosis factor inhibitor drugs market size is anticipated to reach USD 42.1 billion by 2026, according to a report published by Grand View Research, Inc. Increasing prevalence of autoimmune diseases, rapid technological advancements, and rise in healthcare expenditure across the globe are some of the major factors expected to drive the growth.

Currently, there are five approved TNF inhibitor drugs in the market- Humira (adalimumab), Enbrel (etanercept), Remicade (infliximab), Simponi/Simponi Aria (golimumab), and Cimzia (certolizumab). Biosimilar versions of Humira, Enbrel, and Remicade have been launched, causing a significant paradigm shift in the market.

The wave of biosimilars pose a significant internal threat to the biologics sale as biosimilars have a comparable efficiency as the original products. The cost-effectiveness of biosimilars makes them an attractive choice in economically sensitive areas. In addition, emerging countries, such as India, China, and South Korea are active participants in the biosimilar market.

Some of the key therapeutic areas involving treatment with TNF inhibitor drugs are rheumatoid arthritis, psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. Although these medicines are mostly used for the treatment of autoimmune diseases, several ongoing studies are investigating the role of TNF inhibitors in the treatment of cancer and other inflammatory conditions.

Some of the key players in the TNF inhibitor space are involved in strategic initiatives, such as mergers and acquisitions and joint ventures for the co-development of products. In addition, patent infringement issues between the manufacturers makes the market dynamics intensely competitive. For instance, AbbVie resolved an issue with Boehringer Ingelheim, regarding Humira’s intellectual property (IP) rights. As per the terms of the agreement, Boehringer Ingelheim received a non-exclusive license to Humira’s IP in the U.S.- scheduled to begin in July 2023.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/tumor-necrosis-factor-tnf-inhibitor-drugs-market

Further key findings from the study suggest:

  • Humira accounted for nearly half the revenue share of TNF inhibitor drugs market in 2018
  • Emergence of biosimilars is anticipated to be the major growth rendering driver for the market
  • Psoriasis is projected to be the most rapidly growing application segment over the forecast period
  • Increased adoption of e-commerce is a key driver for online pharmacies
  • TNF inhibitors faces an external threat from IL-inhibitors

Scleroderma Therapeutics Market Size Worth $2.6 Billion By 2026

The global scleroderma therapeutics market size is expected to reach over USD 2.6 billion by 2026 registering a CAGR of 6.0%, according to a new study by Grand View Research, Inc. The market growth is credited to the availability of various therapies used off-label, such as small molecule therapies including branded, generics, and OTC drugs.

The mix of several indications and drug classes engenders a fragmented market with multiple players. Roche is the dominant company with biologic immunosuppressants, Actemra/RoActemra, Cellcept, and Rituxan contributing majorly to the company’s share. Pfizer and Eli Lilly are the key companies in the market. Over the forecast period, new entrants including Boehringer Ingelheim, Corbus Pharmaceuticals, and Fibrocell will marginally displace the share of established firms in this market.

The on-label market is in the development phase. Supplemental indication approval is one of the most common strategies adopted by market participants. For example, riociguat by Bayer was previously used for PAH and currently, it is under clinical trials for the treatment of SSc-related digital ulcers. There are several other pharmaceutical companies following suit as this strategy favors the pharmaceutical industry in offsetting high development costs and in reaping larger benefits from one molecule already developed and present in the market.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/scleroderma-therapeutics-market

Further key findings from the study suggest:

  • The immunosuppressants segment held the largest market share in 2018 and is likely to maintain the dominance throughout the forecast years
  • High preference for immunosuppressants owing to the favorable reimbursement scenario associated with this drug class supports its dominant market share
  • Systemic scleroderma indication segment accounted for the major market share and will expand further due to use of high-priced immunosuppressants
  • U.S. held the majority of the share in 2018. Expected label expansions and expected launch of first-in-class therapies coupled with an evolving reimbursement landscape for orphan drugs support continual scleroderma therapeutics market growth
  • Europe trails with a lower share as compared to the U.S. majorly due to higher use of generics and biosimilars for off-label treatment of scleroderma
  • Some of the key companies are F. Hoffman La-Roche Ltd.; Bristol-Myers Squibb Company; Celgene Corp.; arGentis Pharmaceuticals, LLC; Bayer AG; Boehringer Ingelheim International GmbH; Akashi Therapeutics; Prometic Life Sciences, Inc.; Emerald Health Pharmaceuticals; Kadmon Holdings, Inc.; Seattle Genetics, Inc.; Cytori Therapeutics, Inc.; Fibrocell Science, Inc.; Chemomab; Corbus Pharmaceuticals Holdings, Inc.; and Genkyotex SA

Uveitis Treatment Market Worth $765.31 Million By 2026

The global uveitis treatment market size is expected to reach USD 765.31 million by 2026, according to a new report by Grand View Research, Inc. It is projected to register a CAGR of 5.8% during the forecast period. Rising prevalence of the condition is anticipated to drive the growth. For instance, according to The Ocular Immunology and Uveitis Foundation, around 43,000 new eye inflammation cases are being diagnosed each year in U.S.

Eye inflammation is also very prevalent among children. However, majority of the affected population ranges from 20 to 50 years of age. Growing geriatric population is also an important factor driving the growth of the market. Rise in number of R&D activities aiming at new drug development is another attribute increasing the demand for these treatments.

For instance, ADX-102 Ophthalmic Solution, by Aldeyra Therapeutics, Inc. is in Phase 2 clinical trial for the treatment of noninfectious anterior uveitis. The National Eye Institute is also engaged in conducting and supporting various research studies in this field. Increasing prevalence of infectious diseases is another contributing factor to the market growth. Infectious uveitis surrounds a significant array of potential pathogens, which is likely to pose immense threat to the people affected.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/uveitis-treatment-market

Further key findings from the report suggest:

  • Corticosteroids led the market in 2018 owing to its wide application for treating noninfectious uveitis as well as availability of varied corticosteroids drugs
  • Monoclonal antibodies are expected to exhibit lucrative CAGR over the forecast period due to rising development of novel biologic drugs
  • Anterior held the largest market share in 2018 owing to growing prevalence and tendency of recurrence of anterior uveitis
  • Posterior is anticipated to showcase lucrative growth over the forecast period owing to rise in the number of R&D and clinical trials undergoing for the treatment posterior uveitis
  • Noninfectious segment held significant revenue share in 2018 owing to the wide array of treatment methods coupled with rising cases of the condition
  • Infectious segment is gaining traction in the uveitis treatment market owing to rising prevalence of infectious diseases
  • North America held the largest revenue share in 2018 owing to increasing prevalence of noninfectious uveitis as well as rising healthcare expenditure in this region
  • Asia Pacific is anticipated to exhibit lucrative CAGR over the forecast period due to the rising number of infectious diseases in the developing countries
  • Few major companies are Allergan, Inc.; Valeant Pharmaceutical International, Inc.; Eyegate Pharmaceuticals, Inc.; AbbVie Inc.; Regeneron Pharmaceuticals, Inc; and Santen Pharmaceutical Co., Ltd

Biopharmaceutical 3PL Market Size Worth $120.64 Billion By 2025

The global biopharmaceutical third party logistics market size is expected to reach USD 120.64 billion by 2025, at a CAGR 4.9% over the forecast period, according to a new report by Grand View Research, Inc. The market for biopharmaceutical third party logistics (3PL) is majorly driven by rising demand for temperature controlled logistic services to transport biologics in various regions and growing distribution networks of biopharmaceutical companies to improve their sales. Rising adoption of automated storage and retrieval systems in the emerging countries is an ongoing trend in the pharmaceutical logistics companies that has gained a significant traction.

Furthermore, the trend of shifting from small molecule drugs to biopharmaceuticals, mainly vaccines and biologics, is projected to drive the market. Since, these small molecule drugs are temperature sensitive products, demand for temperature controlled transportation and storage increases and thus is responsible for the market growth. As of now, the pharmaceutical sales through distributors have grown from USD 304.6 billion in 2013 to USD 440.2 billion in 2016. However, the average number of manufacturers per distributor had declined from 1,474 in 2014 to 1,211 in 2016. This data depicts that there is an increase in quantity of pharmaceutical products being distributed, and thus, is expected to surge the demand for 3PL services.

Additionally, environmental concerns and cost have caused a slight shift in the means of transport used for commercial product, moving from airway to seaway shipping and in roadways from truck to intermodal (both rail and truck). The intermodal transport is majorly used by these pharmaceutical companies to reduce the carbon footprint. The ongoing trend shows that the pharmaceutical manufacturers have shifted towards sea freight to reduce the cost and risk factor. Although for cold chain products, the companies still prefer air freight. However, some of the large pharmaceutical companies are planning to transport 70% of their products via ocean freight including cold chain products.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/biopharmaceutical-third-party-logistics-3pl-market

Further key findings from the report suggest:

  • In 2018, non-cold chain logistics held the largest market share in terms of revenue owing to the sales of a large number of drugs that do not require any temperature control
  • Cold chain logistics segment is expected to register the faster CAGR over the forecast period owing to the demand for biologics, such as cellular therapies, vaccines, and test kits
  • Warehousing and storage held the largest market share among the types of services in 2018
  • Asia pacific expected to emerge with the fastest CAGR over the forecast period owing to adoption of medicines from aging population and shift of drug sales from brand manufacturers to generic
  • Key players operating in the biopharmaceutical third party logistics market include DHL International GmbH., SF Express, United Parcel Service of America, Inc, AmerisourceBergen Corporation, DB Schenker, Kuehne and Nagel, Kerry logistics network limited and Agility

Myasthenia Gravis Treatment Market Size Worth $2.06 Billion By 2026

The global myasthenia gravis treatment market size is expected to reach USD 2.06 billion by 2026 at a CAGR of 7.5% through the forecast period, according to a new report by Grand View Research. Increasing awareness of rare diseases, emergence of biologics, and growing adoption of immunotherapies & immunosuppressants are driving the myasthenia gravis (MG) treatment market.

Myasthenia gravis (MG) is a rare autoimmune disorder caused by an antibody mediated neuromuscular transmission obstruction that results in skeletal muscle weakness. Some of the disorders associated with the disease include drooping eyelids, double vision, trouble walking, and trouble talking. Patients with MG present with painless muscle weakness that worsens with repeated use and improves with rest.

According to the National Organization for Rare Disorders (NORD), in the U.S. around 14-40 per 100,000 individuals suffer from myasthenia gravis. Reports suggest that the frequency of the disorder is on the rise over the last several decades. This can be attributed to the better identification of patients and the increasing prevalence of autoimmune disorders among general public across the world. Myasthenia gravis occurs more frequently in females than in males, and although symptoms may appear at any age, its onset usually peaks in men in their 50s or 60s and in women during their 20s or 30s.

Medication held the largest market share in the treatment segment and is expected to maintain its market leading position through the forecast period. This is because medications can largely manage the symptoms and dramatically inhibit the immune system. Medications include immunotherapies such as Soliris (eculizumab), corticosteroids, and immunosuppressive drugs such as Prograf (tacrolimus) and Neoral/Sandimmune (cyclosporine). However, high cost of treatment and lack of awareness in the developing & underdeveloped countries are expected to inhibit the market growth.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/myasthenia-gravis-mg-treatment-market

Further Key Findings From the Study Suggest:

  • Medications are expected to obtain the largest market share in the treatment segment. This can be attributed to the high adoption of immunotherapies and the recent approval of promising drugs.
  • Currently, no cure is available for myasthenia gravis, however patients can be treated with medications and surgery for the management of the symptoms.
  • North America is likely to dominate the MG treatment market due high healthcare expenditure and favorable reimbursement scenario
  • The Asia Pacific region is expected to grow at the highest CAGR over the forecast period due to improving healthcare infrastructure and increasing disposable income in the region.
  • Some of the major companies operating in the market include Alexion Pharmaceutical Inc., Grifols SA, Avadel Pharmaceuticals plc. Novartis AG, Pfizer, Inc., AbbVie Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Bausch Health Companies Inc., and Shire plc.

Acute Repetitive Seizures Market Size Worth $3.19 Billion By 2025

The global acute repetitive seizures market size is expected to reach USD 3.19 billion by 2025, according to a new report by Grand View Research, Inc. The report also states that the market will expand at a strong CAGR of 47.8% during the forecast period. Rise in the number of initiatives to increase awareness about epilepsy is the major factor driving the market.

The market is currently led by generic drugs which mainly include oral benzodiazepines (diazepam and lorazepam). Rectal diazepam is the only approved drug for use in U.S. and buccal midazolam in the European Union. Other drugs, such as diazepam (oral and intramuscular), midazolam (buccal, intranasal, intramuscular), lorazepam (oral, intranasal, sublingual), and progesterone are majorly used off label. The market is expected to be consolidated with a few major companies and a high market share.

Furthermore, in an attempt to curb healthcare expenditure, governments are making continuous efforts to reduce hospital stays and on-site treatment costs via outpatient care models, such as clinic and home healthcare. Emerging economies like India and China, are increasingly implementing such healthcare reform, which is expected to propel the growth of acute repetitive seizures market.

There are several routes of drug administration; out of which, the nasal route is the most preferred over others, such as buccal, rectal, and parenteral. The buccal route is preferred by caregivers and parents for children suffering from pediatric seizures since medication can be administered even outside the hospital.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/acute-repetitive-seizures-market

Further key findings from the study suggest:

  • Global acute repetitive seizures market size was estimated at USD 140.5 million in 2017 and is expected to register a CAGR of 47.8% over the forecast period
  • Diastat rectal gel was the dominant product segment in 2017 due to the efficacy of the route of administration and affordability of the product
  • USL-261 is expected to witness a lucrative CAGR over the forecast period. USL-21 has an edge over the other drugs owing to its superior clinical profile and positive phase III results
  • North America held the largest share in 2017 due to factors, such as growing initiatives for raising awareness about epilepsy and seizures
  • Germany is anticipated to witness lucrative growth over the next decade owing to technological advancements in scientific, clinical, and medical fields
  • Some of the key companies in the market are UCB S.A.; Neurelis, Inc.; and Alexza Pharmaceuticals, Inc. These companies are likely to dominate the market and gain maximum share over the forecast period

Healthcare Cyber Security Market Worth $10.85 Billion By 2022

Global healthcare cyber security market size is expected to reach nearly USD 10,848.87million by 2022, according to a new report by Grand View Research, Inc. Key factors attributing to the growth of the market include the increasing incidences of cyber attacks for misuse of electronic patient health records (E-PHR), social security records, IP theft, and others. 

Cyber attacks are constantly increasing across the globe. On previous encounters it was witnessed that cyber attacks were focused on stealing, financial information, billing information, and bank account numbers using stolen devices with un-encrypted data, phishing and spam mails. Technological advancements have led to advanced cyber warfare using SQL injections, advanced persistent threats (APT), zero day attacks, and advanced malware. 

Lack of adequate IT spending by healthcare organizations and lack of awareness about cyber crime have exposed the vulnerabilities of healthcare organizations. The overall impact of cyber attacks on the hospitals and healthcare systems is estimated to be nearly six billion per year. 

Furthermore, these organizations face internal threats due to factors such as the use of cloud services, unsecure networks, employee negligence, bring your own device (BYOD), lack of internal identification and security systems, stolen devices with un-encrypted files. 

Healthcare cyber security market is segmented by, type of threat into malware, ddos, advanced persistent threat (apt), spyware, lost and stolen devices, others. In 2013, Boston Scientific, St.Jude Medical and, Medtronic witnessed cyber attacks and hacking. In 2015, Anthem, which is the second largest health insurance provider in the U.S., witnessed a massive cyber attack leading to loss of 80 million customer records. 

Security information and event management (SIEM),risk and compliance management, DDoS mitigation, antivirus, antimalware, identity and access management, intrusion detection system (IDS)/intrusion prevention system (IPS) and others are the solutions included in the scope of the study. These solutions can be used individually or can be used as a suite of products providing layer wise security. 

Market dynamics in this sector are dependent on the type of threat, effectiveness, and frequency of attack, ability to detect and destroy. New types of threats are detected each day, hence, the solutions need to be upgraded constantly to provide adequate firewall security and prevent data breach. 

Click the link below:
http://www.grandviewresearch.com/industry-analysis/healthcare-cyber-security-market

Further key findings from the study suggest:

  • In 2014, North America held the largest market share of more than 41% owing to the presence of sophisticated healthcare infrastructure, and increasing collaboration between pharmaceutical, medical device industries, with regulatory authorities. This can be illustrated using the U.S FDA guidance document on networked medical devices.
  • Furthermore, the U.S. is a prime target for cyber crimes due to, the presence of large fortune 500 healthcare organizations, full scale implementation of digital patient records, and use of extensive social security ids for various transactions.
  • Asia Pacific is identified as one of the most lucrative regional market, growing at a CAGR of over 8.5% during the forecast period. Rapidly improving healthcare infrastructure and high level economic growth in developing countries such as China, India, and South Korea is expected to boost usage rates over the forecast period.
  • Increasing number of internet users in China and India is expected to create a huge user base vulnerable to cyber attacks. According to data published by the Internet and Mobile Association of India (IAMAI), the internet user base in India is expected to reach nearly 402 million by December 2015
  • Key players operating in the healthcare cyber security market include, Cisco, IBM, MacAfee, Paulo Alto Networks, Symantec, Trend Micro Lockheed Martin, FireEye, Northrop Grumma, Kaspersky etc.